Gemita Ingredients and Usage

The active ingredient is Gemcitabine Hydrochloride, a nucleoside analog that inhibits DNA synthesis. It is administered as an intravenous infusion over 30 minutes, typically on days 1, 8, and 15 of a 28-day cycle, with dosage based on body surface area and specific cancer protocol.

Gemita is clinically indicated for:

• Locally advanced or metastatic pancreatic cancer
• Non-small cell lung cancer
• Metastatic breast cancer
• Advanced ovarian cancer
• Bladder cancer and other solid tumors

How Does Gemita Work?

Gemita provides antineoplastic activity through multiple mechanisms:

1. DNA Incorporation: Incorporated into DNA causing masked chain termination
2. Ribonucleotide Reductase Inhibition: Inhibits enzymes essential for DNA synthesis
3. Cell Cycle Arrest: Arrests cells at the G1/S-phase boundary
4. Apoptosis Induction: Promotes programmed cell death in cancer cells

Gemita Side Effects and Warnings

Common side effects include myelosuppression, nausea, vomiting, rash, fever, flu-like symptoms, and elevated liver enzymes. Most adverse effects are manageable with supportive care.

Serious Considerations

1. Myelosuppression: Causes significant bone marrow suppression requiring regular blood monitoring
2. Pulmonary Toxicity: May cause severe pulmonary toxicity including ARDS and pulmonary fibrosis
3. Hemolytic Uremic Syndrome: Rare but serious renal and hematological toxicity
4. Hepatic Toxicity: Can cause elevated liver enzymes and hepatic failure
5. Capillary Leak Syndrome: May cause fluid retention and edema

Gemita Storage Conditions

Gemita Injection requires proper storage conditions:

• Store unreconstituted vials at 15-30°C
• Protect from light and moisture
• Use reconstituted solution immediately or refrigerate for up to 24 hours
• Do not freeze reconstituted solution
• Discard unused portions appropriately